Gupta S, Dominguez M, Golestaneh L. Diabetic kidney disease: an update. Med Clin North Am. 2023;107(4):689–705.

Article  PubMed  Google Scholar 

Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291–312.

Article  PubMed  CAS  Google Scholar 

Halminen J, Sattar N, Rawshani A, Eliasson B, Eeg-Olofsson K, Bhatt DL, Rawshani A. Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes. Diabetes Care. 2022;45(10):2326–35.

Article  PubMed  Google Scholar 

Zhu L, Han J, Yuan R, Xue L, Pang W. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res. 2018;51(1):9.

Article  PubMed  PubMed Central  Google Scholar 

Wang J, Zhao SM. LncRNA-antisense non-coding RNA in the INK4 locus promotes pyroptosis via miR-497/thioredoxin-interacting protein axis in diabetic nephropathy. Life Sci. 2021;264: 118728.

Article  PubMed  CAS  Google Scholar 

Kuwagata S, Kume S, Chin-Kanasaki M, Araki H, Araki S, Nakazawa J, Sugaya T, Koya D, Haneda M, Maegawa H, et al. Microrna148b-3p inhibits mTORC1-dependent apoptosis in diabetes by repressing TNFR2 in proximal tubular cells. Kidney Int. 2016;90(6):1211–25.

Article  PubMed  CAS  Google Scholar 

Hou Y, Tan E, Shi H, Ren X, Wan X, Wu W, Chen Y, Niu H, Zhu G, Li J, et al. Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney. Cell Mol Life Sci. 2024;81(1):23.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci. 2005;330(2):69–81.

Article  PubMed  Google Scholar 

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727–49.

Article  PubMed  CAS  Google Scholar 

Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Després JP, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636–64.

Article  PubMed  Google Scholar 

Huang TS, Wu T, Wu YD, Li XH, Tan J, Shen CH, Xiong SJ, Feng ZQ, Gao SF, Li H, et al. Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice. Nat Commun. 2023;14(1):390.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lee SJ, Joo JH, Park S, Kim C, Choi DW, Hong SJ, Ahn CM, Kim JS, Kim BK, Ko YG, et al. Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2023;82(5):401–10.

Article  PubMed  Google Scholar 

Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562–74.

Article  PubMed  CAS  Google Scholar 

Yang X, Okamura DM, Lu X, Chen Y, Moorhead J, Varghese Z, Ruan XZ. CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol. 2017;13(12):769–81.

Article  PubMed  CAS  Google Scholar 

McClintick DJ, O’Donoghue ML, De Ferrari GM, Ferreira J, Ran X, Im K, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, et al. Long-term efficacy of evolocumab in patients with or without multivessel coronary disease. J Am Coll Cardiol. 2024;83(6):652–64.

Article  PubMed  CAS  Google Scholar 

Wu L, Zhang B, Li C, Zhuang Z, Liu K, Chen H, Zhu S, Zhu J, Dai Z, Huang H, et al. PSCK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis. J Neurol Neurosurg Psychiatry. 2024;95(6):529–35.

Article  PubMed  Google Scholar 

Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, Baragetti A, Arnaboldi L, De Metrio S, Pellegatta F, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019;40(4):357–68.

Article  PubMed  Google Scholar 

Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928–33.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bordicchia M, Spannella F, Ferretti G, Bacchetti T, Vignini A, Di Pentima C, Mazzanti L, Sarzani R. PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides. Int J Mol Sci. 2019;20(2): 245.

Article  PubMed  PubMed Central  Google Scholar 

Suzuki T, Iyoda M, Kanazawa N, Tachibana S, Honda H. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on podocytes in mouse nephrotic syndrome. Lab Invest. 2023;103(9): 100199.

Article  PubMed  CAS  Google Scholar 

Gao M, Tang M, Ho W, Teng Y, Chen Q, Bu L, Xu X, Zhang XQ. Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis. ACS Nano. 2023;17(18):17721–39.

Article  PubMed  CAS  Google Scholar 

Guo Y, Tang Z, Yan B, Yin H, Tai S, Peng J, Cui Y, Gui Y, Belke D, Zhou S, et al. PCSK9 (proprotein convertase subtilisin/kexin type 9) triggers vascular smooth muscle cell senescence and apoptosis: implication of its direct role in degenerative vascular disease. Arterioscler Thromb Vasc Biol. 2022;42(1):67–86.

Article  PubMed  CAS  Google Scholar 

Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, Zhu Y, Shi H, He Y, Xie L. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13.

Article  PubMed  PubMed Central  Google Scholar 

Berg DD, Moura FA, Bellavia A, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Bohula EA, Giugliano RP, Park JG, et al. Assessment of atherothrombotic risk in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2023;81(25):2391–402.

Article  PubMed  PubMed Central  Google Scholar 

Yang CL, Zeng YD, Hu ZX, Liang H. Pcsk9 promotes the secretion of pro-inflammatory cytokines by macrophages to aggravate H/R-induced cardiomyocyte injury via activating NF-κB signalling. Gen Physiol Biophys. 2020;39(2):123–34.

Article  PubMed  Google Scholar 

Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, Wang Z, Wei DH, Liu LS, Zheng XL, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis. 2017;262:113–22.

Article  PubMed  CAS  Google Scholar 

Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383(14):1317–27.

Article  PubMed  CAS  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

Article  PubMed  CAS  Google Scholar 

Ruscica M, Macchi C, Giuliani A, Rizzuto AS, Ramini D, Sbriscia M, Carugo S, Bonfigli AR, Corsini A, Olivieri F, et al. Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study. Cardiovasc Diabetol. 2023;22(1): 222.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Feng Z, Liao X, Zhang H, Peng J, Huang Z, Yi B. Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus. Ren Fail. 2023;45(1): 2215880.